Immune checkpoint inhibitor‐associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series

• Published in: Asia-Pacific journal of clinical oncology Vol. 17; no. 5; pp. e262 - e267
• Main Authors: Wong, Evelyn Yi Ting, Yong, Ming Hui, Yong, Kok Pin, Tan, Eng Huat, Toh, Chee Keong, Kanesvaran, Ravindran, Takano, Angela, Ng, Quan Sing
• Format: Journal Article
• Language: English
• Published: Chichester Wiley Subscription Services, Inc 01.10.2021
• Subjects: Immune checkpoint inhibitors; Lymphocytes T; Medical records; Metastases; Myasthenia; Myasthenia gravis; Myositis; Neuromuscular junctions; Patients
• ISSN: 1743-7555; 1743-7563
• DOI: 10.1111/ajco.13442

Immune checkpoint inhibitors (ICI) have improved survival across tumor types however they cause immune‐related toxicities through removal of the inhibition of auto‐reactive T cells. In this case review, we present 4 patients with metastatic cancer who developed de‐novo neuromuscular side effects of myositis with overlapping seropositive myasthenia gravis after ICI treatment. Declaration: This study was performed in accordance to the ethical standards set by the SingHealth Institutional Review Board, with consent taken from living patients and waiver of consent from deceased patients (CIRB Ref 2019/2485). Supporting data were collected from our institution's digital medical records system. Immune checkpoint inhibitors (ICIs) have improved survival across tumor types, however they cause immune‐related toxicities through removal of the inhibition of auto‐reactive T cells. In this case review, we present four patients with metastatic cancer who developed de‐novo neuromuscular side effects of myositis with overlapping seropositive MG after ICI treatment.